Immune and allergenic effects of the microalga Coccomyxa sp. strain KJ in healthy humans: A pilot study.

Coccomyxa sp. KJ allergic reactions immune functions

Journal

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
ISSN: 1899-5276
Titre abrégé: Adv Clin Exp Med
Pays: Poland
ID NLM: 101138582

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 14 12 2022
revised: 15 02 2023
accepted: 31 05 2023
medline: 30 6 2023
pubmed: 30 6 2023
entrez: 30 6 2023
Statut: aheadofprint

Résumé

The Coccomyxa sp. strain KJ (Coccomyxa KJ), a microalga found in Japan, has a potential function in controlling viral infections. Recently, its dry powder has been marketed as a health food product. This pilot study investigated the effects of Coccomyxa KJ powder tablet intake on allergic reactions and immune functions in healthy participants. Nine healthy volunteers (4 males and 5 females) who expressed interest in foods containing Coccomyxa KJ, and were willing to undergo blood tests, were recruited. Each individual was asked to take 2 Coccomyxa KJ powder tablets (0.3 g) before breakfast once a day for 4 weeks. The salivary immunoglobulin A (IgA) level and blood parameters (white blood cell (WBC) count, eosinophil and lymphocyte counts and percentages, natural killer (NK) cell activity, interleukin (IL)-6 level, and T helper (Th)1/Th2 cell ratio) were evaluated at baseline and weeks 2 and 4. The 4-week intake of Coccomyxa KJ did not affect salivary IgA levels, WBC count, eosinophil and lymphocyte counts and percentages, or the Th1/Th2 ratio. There were significant differences in the NK cell activity after 4 weeks, with an average increase of 11.78 (95% confidence interval (95% CI): 6.80-16.76). None of the patients experienced adverse reactions during or after the study. Long-term Coccomyxa KJ intake improved NK cell activity without causing adverse effects on the indicators of local immunity, systemic inflammation and immune response balance. This study suggests that Coccomyxa KJ powder tablets can induce beneficial immune modifications without causing any adverse effects.

Sections du résumé

BACKGROUND BACKGROUND
The Coccomyxa sp. strain KJ (Coccomyxa KJ), a microalga found in Japan, has a potential function in controlling viral infections. Recently, its dry powder has been marketed as a health food product.
OBJECTIVES OBJECTIVE
This pilot study investigated the effects of Coccomyxa KJ powder tablet intake on allergic reactions and immune functions in healthy participants.
MATERIAL AND METHODS METHODS
Nine healthy volunteers (4 males and 5 females) who expressed interest in foods containing Coccomyxa KJ, and were willing to undergo blood tests, were recruited. Each individual was asked to take 2 Coccomyxa KJ powder tablets (0.3 g) before breakfast once a day for 4 weeks. The salivary immunoglobulin A (IgA) level and blood parameters (white blood cell (WBC) count, eosinophil and lymphocyte counts and percentages, natural killer (NK) cell activity, interleukin (IL)-6 level, and T helper (Th)1/Th2 cell ratio) were evaluated at baseline and weeks 2 and 4.
RESULTS RESULTS
The 4-week intake of Coccomyxa KJ did not affect salivary IgA levels, WBC count, eosinophil and lymphocyte counts and percentages, or the Th1/Th2 ratio. There were significant differences in the NK cell activity after 4 weeks, with an average increase of 11.78 (95% confidence interval (95% CI): 6.80-16.76). None of the patients experienced adverse reactions during or after the study.
CONCLUSIONS CONCLUSIONS
Long-term Coccomyxa KJ intake improved NK cell activity without causing adverse effects on the indicators of local immunity, systemic inflammation and immune response balance. This study suggests that Coccomyxa KJ powder tablets can induce beneficial immune modifications without causing any adverse effects.

Identifiants

pubmed: 37386858
doi: 10.17219/acem/166665
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Satomi Asai (S)

Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.

Kyoko Hayashi (K)

Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.
Department of Clinical Engineering, College of Life and Health Sciences, Chubu University, Kasugai, Japan.

Haruyo Atsumi (H)

Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.

Mika Doi (M)

Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.

Hidehumi Kakizoe (H)

Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.

Kazuo Umezawa (K)

Department of Emergency and Critical Care, Tokai University School of Medicine, Isehara, Japan.

Akihumi Hisada (A)

Clinical Laboratory Center, Tokai University Hospital, Isehara, Japan.

Tsukasa Nozaki (T)

Clinical Laboratory Center, Tokai University Hospital, Isehara, Japan.

Akiko Kanno (A)

DENSO Corporation, Kariya, Japan.

Satoko Komatsu (S)

DENSO Corporation, Kariya, Japan.

Hitoshi Kuno (H)

DENSO Corporation, Kariya, Japan.

Kentaro Wakamatsu (K)

National Hospital Organization Omuta National Hospital, Japan.

Toshio Kawahara (T)

Department of Clinical Engineering, College of Life and Health Sciences, Chubu University, Kasugai, Japan.

Yoshiro Yamamoto (Y)

Department of Mathematics, Faculty of Science, Tokai University, Hiratsuka, Japan.

Hayato Miyachi (H)

Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.

Classifications MeSH